Despite efforts by the manufacturer to reduce the cost of Avastin, the clinical effectiveness agency for England and Wales says that it will not recommend the drug for the... More »
The combination of oxaliplatin plus fluorouracil/leucovorin is known as the FOLFOX regimen, and it has become a standard regimen for colorectal cancer (CRC), both as adjuvant... More »
Four years ago, at least five years of statin use was found to be associated with a 53% reduction in the risk of colorectal cancer and that association still stands, according... More »
BERLIN—A pair of colon cancer trials using panitumumab (Vectibix) not only proved the efficacy of the drug in patients with nonmutated KRAS but also highlighted the importance... More »
The combined-modality care of the patient with colon or rectal cancer metastatic to the liver demands a team approach. It is little wonder that there is much confusion about... More »
BERLIN—The failure of a major colon cancer trial to reach its primary endpoint surprised even the most seasoned gastrointestinal cancer investigators. Overall survival was not... More »
Since the early 1990s, postoperative adjuvant chemoradiotherapy was widely viewed as the main approach to treat patients with stage II and III rectal cancer. Over the past few... More »
SAN FRANCISCO—Routine KRAS testing in colon cancer patients received a major boost in January when ASCO issued a provisional clinical statement in favor of pretreatment... More »
STOCKHOLM—For rectal cancer patients, a multidisciplinary team is critical to success because it increases the possibility of a curative resection, Andres Cervantes, MD,... More »
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. According to the most recent data from NCI, the relative five-year survival rate... More »
The treatment of older patients with colorectal cancer is not always straightforward. As highlighted in the article by Dr. Ades, the heterogeneity of physiologic aging, the... More »
Exiqon A/S has released its miRNAbased prognostic test designed to identify stage II colon cancer patients who may be at significantly higher risk for recurrence and for whom... More »
In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
This supplement and associated publication costs were funded by Genomic Health.
